Pulmonary, Critical Care, and Sleep Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Assess Physician Preferences for Electronic Chart Review and Historical Information Needs for New Patient Encounters in the ICU

   Rochester, Minn.

   The purpose of this study is to develop an interactive medical record timeline based on physician preferences and perceived clinical needs, to improve the chart review process for new patient encounters in the ICU.

2. Mindful Breathing Awareness Through Pursed-Lip Breathing Training

   Rochester, Minn.

   To establish the feasibility of a tool that monitors and motivates people with COPD to complete training in mindful pursed-lip breathing to enhance pulmonary rehabilitation at home.

3. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

   Scottsdale/Phoenix, Ariz.

   This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).

4. A Study to Compare Transverse Diagnostic Methods in Pediatric Patients After Polysomnogram for Diagnosis of Obstructive Sleep Apnea

   Rochester, Minn.

   The primary purpose of this study is to analyze maxillary transverse dimensions in children who have completed polysomnography (PSG), using McNamara’s Criteria and Andrew’s Six Elements.

5. Treating Sleep Apnea Induced Hypoxemia With Oxygen in Acute Stroke Patients

   Rochester, Minn.

   We want to determine if treating acute ischemic stroke patients who have evidence of hypoxemia due to sleep apnea with low flow O2 during sleep might help improve clinical and functional outcomes.

6. Impulse Oscillometry in Idiopathic Subglottic StenosisCap

   Rochester, Minn.

   The purpose of this study is to describe impulse oscillometry (IOS) in patients with symptomatic idiopathic subglottic stenosis (iSGS). The study will also compare IOS findings in patients with iSGS with IOS findings in patients with small airways obstruction and in healthy controls.

    

7. Real Time Detection of Electrophysiologic Disturbances Following Subdural Hematoma Evacuation

   Rochester, Minn.

   The purpose of this study is to detect and characterizer electrophysiologic disturbances (such as local field potentials) in patients with underrecognized cause of coma, focal deficits and prolonged encephalopathy following subdural hematoma (SDH) evacuation.

8. Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

   Rochester, Minn.

   The purpose of this clinical trial is to determine if low dose naltrexone is effective in improving health-related quality of life (HRQoL) among patients with vasculitis. Although it is a pilot study, a placebo-controlled component is used because of the prominent placebo group effect seen in studies with self-reported subjective outcomes.

   Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis.

9. A Study to Evaluate Whether or Not Selexipag is Effective and Safe in Patients with Chronic Thromboembolic Pulmonary Hypertension when the Disease is Inoperable or Persistent/Recurrent After Surgery

   Jacksonville, Fla.

   The primary objective of this study is to evaluate the effect of selexipag on pulmonary vascular resistance (PVR) versus placebo in subjects with inoperable CTEPH (i.e., technically non-operable) and persistent/recurrent CTEPH after surgical (pulmonary endarterectomy [PEA]) and/or interventional (balloon pulmonary angioplasty [BPA] treatment at Week 20.
   
   The secondary objectives are to evaluate the effects of selexipag versus placebo on exercise capacity, rate of death or hospitalizations related to Pulmonary Hypertension (PH) worsening, time to clinical worsening, WHO functional class (FC), patient reported outcomes, dyspnea, and N-terminal pro b-type natriuretic peptide (NT-proBNP).

10. Influence of Immunosuppresion on Lung Iron Content in Pneumonia

    Scottsdale/Phoenix, Ariz.

    The purpose of the study is to see whether lung concentrations of iron and a protein that binds iron are influenced by the presence of pneumonia. Increased amounts of iron in the lungs may promote the growth or microorganisms and may influence the severity of lung injury caused by an infection. We are comparing the amount of iron that accumulates in the lungs in response to pneumonia in different types of patients.